Andrey Loboda

List of Publications by Year
in descending order

19	8,093	516710 16	752698 20
papers	citations	h-index	g-index

21	21	21	14064
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	IFN-Î³â€“related mRNA profile predicts clinical response to PD-1 blockade. Journal of Clinical Investigation, 2017, 127, 2930-2940.	8.2	2,560
2	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	30.7	1,592
3	Pan-tumor genomic biomarkers for PD-1 checkpoint blockadeâ€“based immunotherapy. Science, 2018, 362, .	12.6	1,575
4	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine, 2018, 24, 1449-1458.	30.7	1,071
5	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell, 2017, 32, 654-668.e5.	16.8	457
6	Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling. American Journal of Pathology, 2011, 179, 37-45.	3.8	269
7	A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics, 2010, 3, 26.	1.5	124
8	Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. Journal of Experimental Medicine, 2021, 218, .	8.5	123
9	Diurnal variation of the human adipose transcriptome and the link to metabolic disease. BMC Medical Genomics, 2009, 2, 7.	1.5	93
10	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	10.8	34
11	Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. Clinical Cancer Research, 2019, 25, 1564-1573.	7.0	33
12	ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. Molecular Cancer Research, 2021, 19, 702-716.	3.4	32
13	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. Clinical Cancer Research, 2022, 28, 1680-1689.	7.0	32
14	Combination of EP ₄ antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. OncoImmunology, 2021, 10, 1896643.	4.6	28
15	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	7.0	21
16	Pre-Treatment Whole Blood Gene Expression Is Associated with 14-Week Response Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging in Infliximab-Treated Rheumatoid Arthritis Patients. PLoS ONE, 2014, 9, e113937.	2.5	18
17	Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate. Journal of Bone and Mineral Research, 2016, 31, 839-851.	2.8	11
18	Reverse Translating Molecular Determinants of Antiâ€“Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models. Molecular Cancer Therapeutics, 2022, 21, 427-439.	4.1	10

#	Article	IF	Citations
19	Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab.. Journal of Clinical Oncology, 2017, 35, 1-1.	1.6	8